<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="656">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152615</url>
  </required_header>
  <id_info>
    <org_study_id>20-02068</org_study_id>
    <nct_id>NCT05152615</nct_id>
  </id_info>
  <brief_title>A Pilot Proof of Concept Study of the Effects of Administration of SCFA in Rheumatoid Arthritis (EASi-RA)</brief_title>
  <official_title>A Pilot Proof of Concept Study of the Effects of Administration of a Short Chain Fatty Acid (SCFA) in Rheumatoid Arthritis (EASi-RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a pilot, proof of concept study to determine the effects of administering an&#xD;
      oral short chain fatty acid (SCFA) supplement along with methotrexate as first line treatment&#xD;
      of new onset rheumatoid arthritis (NORA) patients. Up to 50 participants will be included to&#xD;
      obtain a sample size of at least 16 participants taking the oral supplement. The study team&#xD;
      hypothesizes that oral SCFA will change the participants' gut microbiome and regulatory&#xD;
      immune responses. Clinical data to assess for adverse events, stool, urine samples and&#xD;
      peripheral blood will be collected at baseline, 2 and 4 months with an optional 6-month time&#xD;
      point. Fecal microbiome will be analyzed. Adaptive immune responses will be analyzed from&#xD;
      participant blood samples.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percentage of Circulating T Regulatory Cells (Treg)</measure>
    <time_frame>Baseline, Visit 2 (60 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiota composition after SCFA supplementation</measure>
    <time_frame>Baseline, Visit 2 (60 days), Visit 3 (120 days), Visit 4 (180 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fecal SCFA Concentration after SCFA supplementation</measure>
    <time_frame>Baseline, Visit 2 (60 days), Visit 3 (120 days), Visit 4 (180 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-10 (IL-10) Production Levels after SCFA Supplementation</measure>
    <time_frame>Baseline, Visit 2 (60 days), Visit 3 (120 days), Visit 4 (180 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>New Onset Rheumatoid Arthritis (NORA) Patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NORA patients receiving methotraxate as first line therapy (standard of care) will take additional oral SCFA supplementation for the purposes of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Short Chain Fatty Acids (SCFA) Dietary Supplement</intervention_name>
    <description>Butryate 1000 mg three times daily will be used in this study.</description>
    <arm_group_label>New Onset Rheumatoid Arthritis (NORA) Patient</arm_group_label>
    <other_name>Butyrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. New diagnosis of rheumatoid arthritis (RA) (&lt;6 months) meeting 2010 ACR/EULAR for RA&#xD;
&#xD;
          2. Scheduled to begin treatment with methotrexate at any dose as standard medical care&#xD;
&#xD;
          3. Able and willing to provide written informed consent prior to any study specific&#xD;
             procedures&#xD;
&#xD;
          4. Age 18 years and above at time of enrollment&#xD;
&#xD;
          5. Subjects not excluded based on race or ethnicity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants who are pregnant or are currently breastfeeding&#xD;
&#xD;
          2. History of sensitivity to study compound or any of their excipients&#xD;
&#xD;
          3. Previous intolerance to SCFA or related compounds&#xD;
&#xD;
          4. Current (within 3 months of screening) treatment with csDMARDs&#xD;
&#xD;
          5. Current or past (ever) treatment with biologic therapies (including but not limited to&#xD;
             anti-TNF, anti-IL-17, anti-IL-12/23)&#xD;
&#xD;
          6. Current antibiotic treatment (within 3 months of screening)&#xD;
&#xD;
          7. Current consumption of probiotics (within 3 months of screening)&#xD;
&#xD;
          8. Severe hepatic impairment (eg, ascites and/or clinical signs of coagulopathy)&#xD;
&#xD;
          9. Renal failure (eGFR &lt;30 or requiring dialysis) by history&#xD;
&#xD;
         10. History of other autoimmune disease&#xD;
&#xD;
         11. Current immunodeficiency state (e.g., cancer, HIV, others)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Scher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca B Blank, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca B Blank, MD, PhD</last_name>
    <phone>212-598-6149</phone>
    <email>Rebecca.Blank@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca B Blank, MD, PhD</last_name>
      <email>Rebecca.Blank@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Jose Scher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca B Blank, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>December 8, 2021</last_update_submitted>
  <last_update_submitted_qc>December 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Short Chain Fatty Acid (SCFA)</keyword>
  <keyword>Butyrate</keyword>
  <keyword>Gut Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be available upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Rebecca.Blank@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

